BACKGROUND: Little is known about patient outcomes with advanced Melanoma following Inpatient initiation or continuation of immune checkpoint blockade (ICB). METHODS AND RESULTS: We conducted a single institution retrospective case series of advanced Melanomapatients who initiated ICB as an Inpatient (initial Inpatient cohort, n = 9), or continued ICB as an Inpatient after previously starting as an outpatient (outpatient then Inpatient cohort, n = 5). One patient had a partial response to ICB initiated as an Inpatient, but ultimately died of Melanoma after 13.5 months. Median overall survival for initial Inpatient cohort was 1.0 month (95% CI: 0.2-11.2), and 1.4 months (95% CI: 0.4-58.0) for the outpatient then Inpatient cohort. Three patients were alive >6 months after Inpatient ICB administration. CONCLUSION: Despite overall poor outcomes, some patients may benefit from Inpatient ICB. This study provides additional information for clinicians to appropriately counsel patients on expectations following Inpatient ICB.
